This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Pulmonary Disease, Chronic Obstructive
and you are
over 40
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD. The actuation indicator is integrated into mouthpiece of the ipratropium bromide HFA inhalation aerosol device. As part of Boehringer Ingelheim's program to qualify an actuation indicator for use with the ipratropium bromide HFA inhalation aerosol device, this study is intended to complement the results from the ongoing in-vitro studies.

Provided treatments

  • Device: Ipratropium bromide
Tris trial is registered with FDA with number: NCT00928746. The sponsor of the trial is Boehringer Ingelheim and it is looking for 142 volunteers for the current phase.
Official trial title:
ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)